Ojjaara, momelotinib
Named-patient access overview. Ojjaara is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Ojjaara
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Ojjaara
Ojjaara (momelotinib) is manufactured by GSK and indicated for Myelofibrosis with anemia (intermediate or high risk). It is an oral small molecule (JAK1/JAK2/ACVR1 inhibitor) approved by the US FDA in 2023 and may be accessible to international patients through Named Patient Program or personal-import pathways.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Ojjaara
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Ojjaara for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Ojjaara is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Country coverage
Reserve Meds publishes detailed country deep-dives for our most-requested medications. If you are pursuing Ojjaara for a patient in the UAE, Saudi Arabia, India, Egypt, Pakistan, or another market we serve, submit a request and our clinical team will match the destination to the appropriate regulatory pathway and timeline.
Reserved for you. Ojjaara is in our coordination scope. Country-specific pricing and timing are confirmed once a coordinator reviews your case.
Start a request for Ojjaara
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.